Candidiasis
candidiasis · society: IDSA
Summary
2016 IDSA update on management of candidiasis covering candidemia, invasive candidiasis, and mucosal disease across neutropenic, nonneutropenic, ICU, neonatal, and special-site populations. Major change from 2009 is the elevation of echinocandins to first-line therapy for most candidemia and invasive candidiasis, with fluconazole reserved for selected stable, azole-naive patients. Adds guidance on β-D-glucan and PCR diagnostics, and updates recommendations for endocarditis, endophthalmitis, CNS, intra-abdominal, and urinary tract candidiasis.
Current guideline: IDSA 2016 Candidiasis Guideline · 
download Anki sub-deck
Versions
- 2016 · IDSA — IDSA 2016 Candidiasis Guideline